Ford Hutman Media provides media relations, thought leadership and executive visibility to health, biotech and digital health companies. The firm was founded by Rachel Ford Hutman, a global health industry connector and creative problem solver. Rachel excels at working with the media to bring health stories to life while making them accessible to stakeholders.

Rachel has worked on some of the world’s biggest therapies and medical technologies of all time, including the first RNAi therapy (Alnylam’s ONPATTRO), the first therapy for Duchenne Muscular Dystrophy (Sarepta’s EXONDYS 51), the first technology in the world to personalize insulin 24 hours a day (Medtronic’s MiniMed 670G) and IBM’s AI launch (Watson). She has counseled some of the most well-known health/ technology organizations and developed communications strategies for the world’s biggest brands (Johnson & Johnson, Medtronic, IBM, Best Buy, Takeda, Sanofi, Shire, Brigham & Women’s, NHS, MIT), and held a senior communications role at IBM.


Rachel worked as a journalist before transitioning to communications and has special insight into working with the media. With 15-years of communications experience, she is consistently leveraging her long-standing relationships with global agenda-setting reporters across a range of outlets from CNBC, BBC, YahooFinance!, Al Jazeera, Bloomberg, Reuters, Financial Times, Fast Company, TIME Wired, Forbes, Business Insider, WSJ, NYTs, and key health trades like FierceBiotech, Endpoints, Modern Healthcare, Becker's, Digital Health Journal, GenomeWeb, BioWorld, Drug Discovery Today and many more. Rachel also has investor and analyst relations experience that adds to her ability to highlight market dynamics at play.

Named PRSA's PR Professional of the Year in 2011, Rachel has built a reputation for her energy, creativity and humor.


Provides senior level support for leading pharma/medtech/ healthcare companies at all stages of development

Expert Media Relations

Corporate Thought Leadership

Executive Visibility

Narrative Development

Crisis Management

Drug and Device Product Development


Strategic Partners

Earned Media Coverage